Form 4: Moderna President Stephen Hoge Sells 15,000 Shares Under 10b5-1 Trading Plan

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at a price of $121.12 per share on July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 15, 2024, Stephen Hoge, President of Moderna, Inc., sold 15,000 shares of Moderna's common stock.
• The sale was executed at a price of $121.12 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 15, 2023.
• Following the transaction, Hoge directly owns 1,442,089 shares of Moderna's common stock.
• Hoge also indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for the benefit of his spouse and children.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing trading plan, so it doesn't necessarily indicate a positive or negative outlook.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects, although sales under 10b5-1 plans are often pre-scheduled and may not reflect current sentiment.

Comparison to Industry Standards

• Comparing Stephen Hoge's transactions to other executives in similar biotech companies like BioNTech (BNTX) or Novavax (NVAX) would provide context.
• Analyzing the frequency and size of insider sales across these companies can help determine if Hoge's activity is typical or unusual.
• For example, if other executives are also selling shares under 10b5-1 plans, it might indicate a broader trend in the industry.
• Conversely, if Hoge's sales are significantly larger or more frequent than his peers, it could raise concerns.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, potentially leading to slight downward pressure on the stock price in the short term.
• However, given the pre-planned nature of the sale under a 10b5-1 plan, the impact is likely to be minimal.

Key Dates